🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Non-statin Lipid-Modifying Therapy

Found 17 matching trials

Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin

PHASE3

Primary Objective: To demonstrate the reduction of low-density lipoprotein...

Status

Completed

Location

Investigational Site Number 392028

Start Date

2015-11-30

Trial ID

NCT02584504

Treatments Being Tested

Alirocumab Placebo Atorvastatin Non-statin Lipid-Modifying Therapy Diet Alone

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)

PHASE3

Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that bi...

Status

Completed

Location

Investigational Site Number 840857

Start Date

2012-07

Trial ID

NCT01644175

Treatments Being Tested

Placebo (for alirocumab)Alirocumab Lipid-Modifying Therapy (LMT)

Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)

PHASE4

Peripheral arterial disease (PAD) occurs when arteries become narrowed or h...

Status

Completed

Location

Baylor College of Medicine

Start Date

2004-04

Trial ID

NCT00687076

Treatments Being Tested

Ezetimibe Niaspan Statin therapy Standard care Aspirin Clopidogrel Placebo Niaspan Placebo Ezetimibe Percutaneous transluminal angioplasty (PTA)

Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan

PHASE3

Primary Objective: To demonstrate the reduction of low-density lipoprotein...

Status

Completed

Location

Investigational Site Number 410001

Start Date

2015-01

Trial ID

NCT02289963

Treatments Being Tested

Placebo (for Alirocumab)Alirocumab Lipid-Modifying Therapy (LMT)

Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

PHASE3

Primary Objectives: * To demonstrate the superiority of alirocumab in comp...

Status

Completed

Location

Investigational Site Number 840020

Start Date

2015-10-23

Trial ID

NCT02585778

Treatments Being Tested

Alirocumab Placebo Lipid-Modifying Therapy (LMT)Antihyperglycemic Drug

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant

PHASE3

The purpose of this study is to determine if bempedoic acid (ETC-1002) is e...

Status

Completed

Location

Multiple Locations

Start Date

2016-11-16

Trial ID

NCT02988115

Treatments Being Tested

bempedoic acid placebo

Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

PHASE3

Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that bi...

Status

Completed

Location

Investigational Site Number 840159

Start Date

2012-01

Trial ID

NCT01507831

Treatments Being Tested

Placebo (for alirocumab)Alirocumab Lipid-Modifying Therapy (LMT)

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

PHASE3

Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that bi...

Status

Completed

Location

Investigational Site Number 840417

Start Date

2012-07

Trial ID

NCT01623115

Treatments Being Tested

Alirocumab Placebo (for alirocumab)Lipid Modifying Therapy (LMT)

Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)

PHASE3

The purpose of this study is to see if ETC-1002 (bempedoic acid) is safe an...

Status

Completed

Location

Multiple Locations

Start Date

2016-01-21

Trial ID

NCT02666664

Treatments Being Tested

ETC-1002 Placebo

Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)

PHASE3

This is a randomized, double-blind, placebo-controlled, parallel-group, mul...

Status

Completed

Location

Multiple Locations

Start Date

2012-12

Trial ID

NCT01709500

Treatments Being Tested

LMT (atorvastatin, simvastatin, or rosuvastatin)alirocumab Placebo

Previous Next